AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021

Mount Carmel Register

Nov 9, 2021

AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021 |!| Mount Carmel